All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Not reported Terminated | 2005-005216-24 | 14-daily Oxaliplatin, Gemcitabine, Dexamethasone and Rituximab with subsequent 90-Y-Zevalin-consolidation for the treamtent of aggressive CD-20-positive B-NHL-relapses in patients with inability to to... | 2010-04-17 | due-trials |
Ongoing | 2006-000284-28 | Einfluss einer Behandlung mit dem HMG-CoA Reduktasehemmer Fluvastatin auf die Erektionsfähigkeit bei Patienten mit kardiovaskulären Risikofaktoren und erektiler Dysfunktion | not-yet-due | |
Ongoing | 2007-002119-17 | EPLERAF-Studie: Eplerenon in der Prävention von Vorhofflimmer-Rezidiven nach Kardioversion / [EPLERAF-Study: Eplerenone in the prevention of atrial fibrillation recurrences after cardioversion] | not-yet-due | |
Not reported | 2008-003249-10 | Olmesartan, Oxidant Stress and in Vivo Re-Endothelialization Capacity of Endothelial Progenitor Cells from Patients with Chronic Kidney Disease (OECD Study) | 2012-03-16 | due-trials |
Ongoing | 2009-010207-83 | Effect of Omega-3 Fatty Acids (n3-PUFA, Zodin®) on Post-Prandial Triglyceride Tolerance | not-yet-due | |
Not reported | 2010-019587-36 | Improvement of outcome and reduction of toxicity in elderly patients with CD20+ aggressive B-cell lymphoma by an optimised schedule of the monoclonal antibody rituximab, substitution of conventional b... | 2024-01-18 | due-trials |
Ongoing | 2012-001989-15 | A randomised, placebo controlled, double blind, cross-over, single center clinical Study to investigate the effect of heart rate reduction with ivabradine on endothelial function and vascular stiffnes... | not-yet-due | |
Not reported | 2013-001626-26 | Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver cirrhosis and ascites (INCA trial) Einfluss einer NOD2-Genotyp-gesteuerten Antibiotikaprophylaxe auf das Über... | 2021-10-02 | due-trials |
Completed, report not yet due | 2013-001998-24 | A prospective, multicenter, double blind, placebo-controlled, two-arm parallel group phase 3 trial to evaluate the effect of early postnatal additional high dose oral vitamin A supplementation of 5000... | 2024-05-28 | not-yet-due |
Listed as ongoing, but also has a completion date | 2016-002272-27 | Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to Gemcitabine, ... | 2025-01-15 | bad-data |
Other | 2021-003523-16 | A feasibility trial investigating inductive Apalutamide therapy combined with radical prostatectomy in patients with locally advanced T4 high risk prostate cancer | not-yet-due | |
Other | 2022-001822-31 | Durvalumab (MEDI4736) in combination with consolidative radiochemotherapy and ablative stereotactic radiotherapy in extensive stage SCLC (DuCoRa-SCLC) | not-yet-due |